Pancreatic Cancer Research

ResearcherUniversity of Electronic Science and Technology of ChinaNo recent work listed

Shikai Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4805-8493; OpenAlex author ID A5045870272. Sources: OpenAlex.

Their work

Papers
10 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
28
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper

Papers 10

  1. CDKs Functional Analysis in Low Proliferating Early-Stage Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.26502/jbsb.5107060↗
  2. Pseudogene AK4P1 promotes pancreatic ductal adenocarcinoma progression through relieving miR-375-mediated YAP1 degradation. Last author DOI 10.18632/aging.203921↗
  3. HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer. Co-author DOI 10.7150/thno.69444↗
  4. Overexpressed WDR3 induces the activation of Hippo pathway by interacting with GATA4 in pancreatic cancer. First author DOI 10.1186/s13046-021-01879-w↗
  5. FBP1 binds to the bromodomain of BRD4 to inhibit pancreatic cancer progression. First author PMID 32195024↗
  6. USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1. First author PMID 31497353↗
  7. 3F-Box protein 32 degrades ataxia telangiectasia and Rad3-related and regulates DNA damage response induced by gemcitabine in pancreatic cancer. Co-author DOI 10.3892/ol.2018.8367↗
  8. Microarray expression profile analysis of long non-coding RNAs in pancreatic ductal adenocarcinoma. Last author DOI 10.3892/ijo.2015.3292↗
  9. Ectopic expression of miR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc. Co-author DOI 10.1038/gt.2015.39↗
  10. Overexpression of membrane-type 2 matrix metalloproteinase induced by hypoxia-inducible factor-1α in pancreatic cancer: Implications for tumor progression and … Co-author DOI 10.3892/mco.2014.357↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chong Yang · 5 shared papers, 2018–2022 · strength 0.60
  2. Xin Jin · 5 shared papers, 2018–2022 · strength 0.58
  3. Ping Fan · 4 shared papers, 2014–2020 · strength 0.36
  4. Heshui Wu · 4 shared papers, 2014–2022 · strength 0.33
  5. Dianyun Ren · 2 shared papers, 2021–2022 · strength 0.26
  6. Jingyuan Zhao · 2 shared papers, 2020–2022 · strength 0.26
  7. Yu Zhou · 1 shared paper, 2023 · strength 0.17
  8. Xueliang Gao · 1 shared paper, 2023 · strength 0.17
  9. Juanjuan Ji · 1 shared paper, 2023 · strength 0.17
  10. Yun Zhang · 1 shared paper, 2022 · strength 0.15
  11. Lang Jia · 1 shared paper, 2022 · strength 0.15
  12. Yingke Zhou · 1 shared paper, 2022 · strength 0.14
  13. Penglin Pan · 1 shared paper, 2022 · strength 0.14
  14. Gengdu Qin · 1 shared paper, 2022 · strength 0.14
  15. Yan Sun · 1 shared paper, 2022 · strength 0.14
  16. Taoyu Chen · 1 shared paper, 2022 · strength 0.14
  17. Haixin Yu · 1 shared paper, 2022 · strength 0.14
  18. Wenjie Su · 1 shared paper, 2021 · strength 0.12
  19. Qiang Fu · 1 shared paper, 2021 · strength 0.12
  20. Kun Zhang · 1 shared paper, 2020 · strength 0.12
  21. Zibo Meng · 1 shared paper, 2020 · strength 0.12
  22. Yu Zhou · 1 shared paper, 2016 · strength 0.06
  23. Ming Yang · 1 shared paper, 2015 · strength 0.04
  24. Y. Liu · 1 shared paper, 2015 · strength 0.04
  25. Gang Zhao · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.